Source:http://linkedlifedata.com/resource/pubmed/id/10606227
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
23
|
| pubmed:dateCreated |
2000-1-6
|
| pubmed:abstractText |
5alpha-Reductase type 2, the predominant prostatic isozyme of this protein, converts testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater 5alpha-reductase activity are at increased risk for prostate cancer (CaP). A single nucleotide polymorphism of the 5alpha-reductase type 2 gene (SRD5A2) gives rise to a substitution of leucine (leu) for valine (val) at codon 89 (V89L), the presence of which may affect serum androstanediol glucuronide (AAG) levels. We studied the effect of this polymorphism on the risk of prostate cancer in a prospective, nested, case-control design within the Physicians' Health Study. In all controls (n = 799), the leu allele frequency was 0.30. Among the 386 controls with plasma AAG levels available, there was no significant association between AAG levels and V89L genotype. We also detected no significant association between risk for CaP and genotype [odds ratio: val/val = 1.0 (reference), leu/val = 0.96 (95% confidence interval, 0.76-1.20), and leu/ leu = 0.84 (95% confidence interval, 0.57-1.24)]. These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3-Oxo-5-alpha-Steroid...,
http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Leucine,
http://linkedlifedata.com/resource/pubmed/chemical/Valine,
http://linkedlifedata.com/resource/pubmed/chemical/beta Carotene
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0008-5472
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
59
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5878-81
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:10606227-3-Oxo-5-alpha-Steroid 4-Dehydrogenase,
pubmed-meshheading:10606227-Adult,
pubmed-meshheading:10606227-Aged,
pubmed-meshheading:10606227-Aged, 80 and over,
pubmed-meshheading:10606227-Amino Acid Substitution,
pubmed-meshheading:10606227-Anticarcinogenic Agents,
pubmed-meshheading:10606227-Aspirin,
pubmed-meshheading:10606227-Boston,
pubmed-meshheading:10606227-Double-Blind Method,
pubmed-meshheading:10606227-European Continental Ancestry Group,
pubmed-meshheading:10606227-Heart Diseases,
pubmed-meshheading:10606227-Humans,
pubmed-meshheading:10606227-Isoenzymes,
pubmed-meshheading:10606227-Leucine,
pubmed-meshheading:10606227-Male,
pubmed-meshheading:10606227-Middle Aged,
pubmed-meshheading:10606227-Neoplasms,
pubmed-meshheading:10606227-Polymorphism, Genetic,
pubmed-meshheading:10606227-Prostatic Neoplasms,
pubmed-meshheading:10606227-Risk Factors,
pubmed-meshheading:10606227-Valine,
pubmed-meshheading:10606227-beta Carotene
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
|
| pubmed:affiliation |
Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|